RIG012
Based on 6 publication(s) in Google Scholar
RIG012 is a potent RIG-I inhibitor with an IC50 of 0.71 μM using the NADH-coupled ATPase assay. RIG012 inhibits IFN-β and ISG hRsad2 expression.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.33%
- CAS No.: 2642218-43-5
- Formule: C23H21NO3
- Masse moléculaire:359.42
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) RIG012
More
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
In Vivo Efficacy Study
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
RT-PCR
Activité biologique
RIG012 contains a strong chromophore that absorbs in the visible range (λmax of 470 nm). Upon binding to RIG-I, the 470 nm absorbance band of RIG012 undergoes a dramatic hyperchromic shift to higher intensity values[1].
RIG012 (1, 1.25, 1.5, 2, 2.5, 3, 4 μM) has potent, dose-dependent inhibition of RIG-I signaling in HEK293T cells cotransfected with expression and reporter plasmids[1].
RIG012 (1.25, 2.25, 4.5, 9, 18 μM) has a potent, dose-dependent inhibition of IFN-β and ISG hRsad2 expression in A549 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2642218-43-5
-
Appearance Solid
-
Masse moléculaire 359.42
-
Formule C23H21NO3
-
Color Orange to red
-
SMILES
O=C1N=C2C3=C(C(C(OCC4=CC=CC=C4)=C2C1(CC)CC)=O)C=CC=C3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Oncogene
Targeting VPS4 elicits STING-driven anti-tumor immunity to suppress rhabdomyosarcoma growth. [Abstract]2026 Jun;45(23):2211-2224. PMID: 42032367 -
J Virol
Zika virus-induced fetal demise is triggered by strain- and dose-specific RLR-driven activation of the interferon response in the decidua, placenta, and fetus in Ifnar1-/- mice. [Abstract]2025 Jun 17;99(6):e0066625. PMID: 40401980
RIG012 purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Jun 17;99(6):e0066625. [Abstract]
The concentration of RIG012 in the serum of non-pregnant female mice (n = 3) intraperitoneally injected once with 10 mg/kg was measured by mass spectrometer.
RIG012 purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Jun 17;99(6):e0066625. [Abstract]
RIG012 treatment did not protect against ZIKV-induced fetal demise in Ifnar1−/− mice. Time-mated Ifnar1−/− dams were treated with vehicle or 22.5 mg/kg RIG012 every 12 h from E6.5 to E14 and inoculated with 103 PFU of ZIKV-BRA on E7.5, and the rate of resorption was calculated at E14.5. Data are presented as the percentage of total fetuses (n = 61–100, from 7 to 10 dams per treatment group). Significance was determined by Fisher’s exact test.
RIG012 purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Jun 17;99(6):e0066625. [Abstract]
There were no significant differences in serum titers between vehicle/ZIKV-BRA and RIG012 (I.P, 22.5 mg/kg, every 12 h)/ZIKV-BRA (two-way ANOVA, P > 0.9999). Maternal viremia was assessed via plaque assay at 2, 4, and 7 days post-inoculation (dpi), and significance was determined by two-way ANOVA with Tukey’s multiple comparisons.
RIG012 purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Jun 17;99(6):e0066625. [Abstract]
There was no significant difference in infectious virus at the MFI between vehicle/ZIKV-BRA and RIG012 (I.P, 22.5 mg/kg, every 12 h)/ZIKV-BRA, and fetuses had undetectable levels of infectious ZIKV-BRA virus.Tissue titer was assessed via plaque assay of MFI and fetus samples harvested at E14.5, and significance was determined by two-way ANOVA with Sidak’s multiple comparisons. Significance annotations: ****, P ≤ 0.0001; ns, P > 0.05.
RIG012 purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Jun 17;99(6):e0066625. [Abstract]
Resorbed fetuses have significantly higher relative interferon-stimulated gene expression than their normal counterparts. ZIKV vRNA load measured by qRT-PCR (A), relative Ifnb (B), Rsad2 (C), and Mx1 (D) expression in the MFI and fetus were plotted against the outcome (resorbed vs normal fetal outcome) and separated by treatment (vehicle vs 22.5 mg/kg RIG012). Gene expression levels in E14.5 MFI and fetus samples were measured by qPCR and normalized to Hprt expression. The ddCT was calculated relative to samples harvested from PBS-inoculated controls. Data points represent individual samples. The mean with standard deviation is plotted. Two-way ANOVA with interaction (between treatment and outcome) and Tukey’s multiple comparisons were used to determine significance. Significance annotations: **, P ≤ 0.01; *, P ≤ 0.05; ns, P > 0.05.
-
Mol Immunol
2026 Feb:190:101-109. PMID: 41564652 -
-
-
bioRxiv
Zika virus-induced fetal demise is driven by strain- and dose-specific RLR-driven activation of the interferon response in the decidua, placenta, and fetus in Ifnar1 -/- mice. [Abstract]2025 Feb 13:2025.02.12.637947. PMID: 39990459
Solvant et solubilité
DMSO : 33.33 mg/mL (92.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7823 mL | 13.9113 mL | 27.8226 mL | 69.5565 mL |
| 5 mM | 0.5565 mL | 2.7823 mL | 5.5645 mL | 13.9113 mL | |
| 10 mM | 0.2782 mL | 1.3911 mL | 2.7823 mL | 6.9557 mL | |
| 15 mM | 0.1855 mL | 0.9274 mL | 1.8548 mL | 4.6371 mL | |
| 20 mM | 0.1391 mL | 0.6956 mL | 1.3911 mL | 3.4778 mL | |
| 25 mM | 0.1113 mL | 0.5565 mL | 1.1129 mL | 2.7823 mL | |
| 30 mM | 0.0927 mL | 0.4637 mL | 0.9274 mL | 2.3186 mL | |
| 40 mM | 0.0696 mL | 0.3478 mL | 0.6956 mL | 1.7389 mL | |
| 50 mM | 0.0556 mL | 0.2782 mL | 0.5565 mL | 1.3911 mL | |
| 60 mM | 0.0464 mL | 0.2319 mL | 0.4637 mL | 1.1593 mL | |
| 80 mM | 0.0348 mL | 0.1739 mL | 0.3478 mL | 0.8695 mL |
RIG012 Related Classifications
HY-147124 Related Classifications
Powered by Bioz